Commercial Insight: Asthma & Copd - Combination Products Still Have Blockbuster Potential : Market Research Report

Commercial Insight: Asthma & Copd - Combination Products Still Have Blockbuster Potential

Published by: Datamonitor

Published: Jul. 11, 2007 - 269 Pages

ABOUT DATAMONITOR HEALTHCARE
About the respiratory pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY: Objective of the analysis; Datamonitor insight into the asthma/COPD market; Contributing experts; Related reports
CHAPTER 2 MARKET DEFINITION AND OVERVIEW: Market definition for this report; Indication sales split; Current market situation; Strategic scoping and focus
CHAPTER 3 COUNTRY MARKET ASSESSMENTS: Summary of environmental issues affecting the asthma/COPD market; Opportunities and threats in the seven major markets; Opportunities; Off-label prescribing is popular in the pediatric asthma market; EMEA harmonizes drug approval process; Smaller companies helped by European regulators; Threats; Governments try to stop increasing healthcare expenditure by controlling pricing and reimbursement; Parallel trading threatens return on investment; Asthma and COPD prevalence will remain stable; Non-compliance is particularly common in asthma; Difficulty in conducting clinical trials in COPD; US: opportunities and threats; Asthma/COPD market overview; Opportunities; New asthma clinical trial endpoints open doors; The CFC-HFA switch will lead to a branded salbutamol market; FDA initiatives to decrease product development times; US is the only country to allow direct-to-consumer (DTC) advertising of prescription medicines; Threats; Reimbursement controls are important in decreasing healthcare expenditure in the US; Implementation of Medicare Part D influences US healthcare market; Parallel trading could increase due to Medicare D's 'donut hole'; Prescription Drug User Fee Act (PDUFA) likely to increase fees; Reimbursement of nebulized beta2-agonists in COPD are under pressure; Japan: opportunities and threats; Asthma/COPD market overview; Opportunities; Characteristics of Japanese society impact the COPD market in particular; Separation of manufacturing and marketing entities benefits both Japanese and foreign companies; Japan shows initiatives to open their market; Threats; Price cuts still dominate pricing and reimbursement in Japan; Increasing uptake of generics; Lengthy approval process slows down access to the Japanese market; COPD remains underdiagnosed and undertreated; France: opportunities and threats; Asthma/COPD market overview; Opportunities; Generics use is still relatively low in France; Pricing and reimbursement negotiations to be shortened by new agency; Threats; France increases its pricing and reimbursement efforts; Varying formularies influence hospital prescribing; Germany: opportunities and threats; Asthma/COPD market overview; Opportunities; Encouraging environment for novel drug development; ePharmacy and mail-order drugs legalized; Disease management programs encourage patients to be more involved; Threats; Reimbursement controls are important in decreasing healthcare expenditure in Germany; Generic penetration in Germany is relatively high; Germany focuses attention on high doses of medicines for elderly patients; ICS/LABA combinations under scrutiny; Italy: opportunities and threats; Asthma/COPD market overview; Opportunities; Generic drugs play a small role in Italy; Reimbursement negotiations are less restrictive; Threats; Italy increases its pricing and reimbursement efforts; Spain: opportunities and threats; Asthma/COPD market overview; Opportunities; The pharmaceutical industry implements strategies to reduce parallel exportation; Health ministry introduces 'Spanish national formulary'; Threats; The introduction of a new medicines bill increases the focus on cost containment in Spain; The profile of generics is being raised in Spain; UK: opportunities and threats; Asthma/COPD market overview; Opportunities; The UK offers an attractive market; The pricing and reimbursement environment in the UK is relatively non-restrictive; Threats; The UK enjoys a strong generics market; The post-guidance and pre-guidance effects of NICE are a significant concern
CHAPTER 4 FORECAST ANALYSIS: Key events; Inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) combinations; Advair/Seretide will lose first position in ICS/LABA class; Symbicort US approval and SMART approach will boost sales; Foster competes on price; New product launches; Major clinical trials; Additional indications; Patent expiries; Oral anti-inflammatories; Singulair will remain highest selling NSAID but will suffer from generic entry and new competitors; New product launches; Additional indications; Patent expiries; Long-acting anticholinergics (LAMAs); BI tries to differentiate Spiriva before the entry of new competitors; New product launches; Major clinical trials; Additional indications; Patent expiries; Inhaled corticosteroids (ICS); Pulmicort and Flixotide remain the highest-selling ICS products; New product launches; Additional indications; Patent expiries; Long-acting beta2-agonists (LABAs); Serevent and Foradil lead the LABA class; New product launches; Major clinical trials; Patent expiries; Biologicals; Xolair to become blockbuster by 2014; New product launches; Additional indications; Patent expiries; Short-acting beta2-agonists (SABAs); Sepracor's Xopenex franchise to reach revenues of over $1 billion; IVAX/Teva's ProAir set to make most out of CFC-HFA switch in the US; Combivent sales to decline slightly; Short-acting anticholinergics (SAMAs); Other asthma and COPD therapies; Bronchial thermoplasty; Antibiotics; Immunotherapy; Data definitions, limitations and assumptions; Standard Units; Japanese Market Data; Derivation of Sales Forecasts and Pricing Trends; Regional launch dates for new products; Generic Erosion and Pricing Assumptions; The 'Others' class; Forecasts; Forecast methodology
CHAPTER 5 COMMERCIAL IMPACT AND LIFECYCLE MANAGEMENT: CASE STUDIES: The strategies behind combination products; Pricing; First-to-market advantage; Patent protection; Combinations are here to stay; The impact of the CFC-HFA switch in the US; HFA as alternative to CFC; 3M's patents will prevent entry of other HFA SABAs; ProAir will be highest-selling SABA after 2009 with peak sales of $650m; The increasing importance of inhaler devices in the asthma/COPD market; Lack of detailed guidelines and physician skills; pMDIs versus DPIs; The ideal inhaler; The Novolizer and the Respimat SMI; The Novolizer - optimal patient feedback and fine particles; The Respimat SMI - slow moving mist with deep lung penetration; BIBLIOGRAPHY; Bibliography
APPENDIX A - MARKET DATA AND MAJOR BRAND KEY FACTS: Summary asthma/COPD market data; ICS/LABA combinations market data; ICS/LABA combinations market data; Anticholinergics market data; Biologicals market data; Oral anti-inflammatories market data; Beta2-agonists market data; Inhaled corticosteroids (ICS) market data
APPENDIX B - MARKET FORECAST DATA: Market forecast data
APPENDIX C: Contributing experts; Report methodology; About Datamonitor; About Datamonitor Healthcare; About the respiratory and infectious disease analysis team; Disclaimer
List of Tables: Table 1: Prescription of off-label and unlicensed drugs in pediatrics; Table 2: Sales of ICS/LABA combination products in the seven major markets ($m), 2006-2016; Table 3: Price difference between launched ICS/LABA combination products in Germany, 2007; Table 4: Sales of oral anti-inflammatory products in the seven major markets ($m), 2006-2016; Table 5: Sales of long-acting anticholinergic products in the seven major markets ($m), 2006-2016; Table 6: Sales of inhaled corticosteroid products in the seven major markets ($m), 2006-2016; Table 7: Sales of long-acting beta2-agonist products in the seven major markets ($m), 2006-2016; Table 8: GSK pool of LABA candidates in Phase II trials, 2006; Table 9: Sales of monoclonal antibody products in the seven major markets ($m), 2006-2016; Table 10: Sales of short-acting betas2-agonist products in the seven major markets ($m), 2006-2016; Table 11: Sales of short-acting anticholinergic products in the seven major markets ($m), 2006-2016; Table 12: Costs per bronchoscopy; Table 13: Launch forecast assumptions used in the asthma/COPD market, 2007; Table 14: Generic erosion in the seven major markets over 3 years (%); Table 15: Generic price discounts in the seven major markets (%); Table 16: Classes rolled up into the 'Others' category by country; Table 17: Prices of HFA (levo)salbutamol products in 2006; Table 18: US - Summary market data, 2006 and 2016; Table 19: Japan - Summary market data, 2006 and 2016; Table 20: France - Summary market data, 2006 and 2016; Table 21: Germany - Summary market data, 2006 and 2016; Table 22: Italy - Summary market data, 2006 and 2016; Table 23: Spain - Summary market data, 2006 and 2016; Table 24: UK - Summary market data, 2006 and 2016; Table 25: Advair/Seretide: key facts; Table 26: Symbicort: key facts; Table 27: Foster: key facts; Table 28: Spiriva: key facts; Table 29: Atrovent: key facts; Table 30: Combivent: key facts; Table 31: Duoneb: key facts; Table 32: Berodual: key facts; Table 33: Xolair: key facts; Table 34: Singulair: key facts; Table 35: Accolate: key facts

Abstract

Introduction

Detailed analysis of the Asthma and COPD market. 10 year sales forecast for all major drugs brands in these indications, taking into account new treatment trends, clinical trial data, patent expirations and key new product launches in the 7 major markets.

Scope

Indication based forecasts for asthma/COPD products and significant pipeline drugs Assessment of country-specific drivers and resistors likely to impact the market Future market outlook for individual products taking into account key market events, in particular patent expiry and competitor launch dates Market overview by geographical area, with value analysis of clinical and commercial factors underlying product performance

Highlights

Asthma/COPD sales in the seven major markets are expected to grow to over $24 billion annually by 2010 and drop slightly thereafter due to patent expiries of key products. The ICS/LABA class is set to remain the leading class by value throughout, while the LAMA market will experience the strongest growth, particularly in COPD. A once-daily LABA/LAMA product should become the top-selling single brand in the seven major markets in 2016, depending on which company launches such a combination product first. However, combined sales of the Advair franchise (Advair/Seretide and once-daily Beyond Advair) will dominate the asthma/COPD market over the next ten years. The phase-out of CFC-containing inhalers in the US after 2008 will have a big impact on the market for short-acting beta2-agonists (SABAs), increasing this class' size significantly. The main beneficiary is expected to be IVAX's (now Teva) ProAir due to its favourable price compared with other marketed HFA SABAs.

Reasons to Purchase

Identify key opportunities and threats that will impact the use and uptake of new and existing products Quantify the future size and

Scope

of the asthma/COPD market and predict the future performance of key compounds Understand and capitalize on clinical unmet needs in the market, either through lifecycle management of marketed drugs or new product development

Please Note: This product is delivered as a zip file,which contains Excel and PDF files.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Commercial Insight: Asthma & Copd - Combination Products Still Have Blockbuster Potential

Table of Contents

Abstract